An Early Phase 1 interventional study of ZM-02-L and ZM-02-H in Retinitis Pigmentosa, sponsored by Zhongmou Therapeutics. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-03-31.
Sponsored by Zhongmou Therapeutics · Early Phase 1, Interventional, and Treatment
This is zM-02's safety, tOlerability, and efficacy in retinitis pigmentOsa first-in-humaN study (MOON). This trial is meant to evaluate the safety and efficacy of ZM-02 in Retinitis pigmentosa (RP) patients. Unilateral intravitreal injections (IVT) will be given into the subject's Study Eye.
Retinitis pigmentosa (RP) is the most common inherited retinal disease. Individuals affected by RP often experience progressive visual impairment, potentially leading to legal blindness. There is currently no established effective clinical treatment available. We developed an innovative adeno-associated virus (AAV)-based gene therapy for individuals with RP, regardless of their causative mutations. Eight to twelve subjects with RP will be recruited and six to nine of them will receive a single unilateral intravitreal injection of ZM-02 at ascending doses, while two to three receive sham injections as the control group.
268 studies on the registry are indexed under Retinitis Pigmentosa; 71 are open to participants now.
This study's planned enrollment of 12 is below the median of 27 across 173 interventional studies indexed under Retinitis Pigmentosa.
Browse Retinitis Pigmentosa studies →Zhongmou Therapeutics is the lead sponsor of 5 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients who meet all of the following criteria can be selected as subjects:
Exclusion Criteria:
Subjects who meet any one of the following exclusion criteria will be excluded from the study:
IVT administration of a single low dose ZM-02 injection
Drug: ZM-02-L
IVT administration of a single high dose ZM-02 injection
Drug: ZM-02-H
Sham IVT injection
Procedure: ZM-02-S
rAAV-PsCatCh2.0 intravitreal injection of low dose
Also known as: rAAV-PsCatCh2.0e, rAAV-PsCatCh2.0
rAAV-PsCatCh2.0 intravitreal injection of high dose
Also known as: rAAV-PsCatCh2.0e, rAAV-PsCatCh2.0
sham intravitreal injection of ZM-02 (not actual injection)
Also known as: Sham injection
Incidence of adverse events and serious adverse events
An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a product; the event will not need to have a causal relationship with the treatment. A serious adverse event (SAE) is any untoward medical occurrence at any dose that leading to the following: Results in death; Life-threatening, refers to an event in which the patient is at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe; Significant or permanent disability/incapacity, where disability refers to a serious disruption and damage of a person's ability to perform normal life functions; Requires inpatient hospitalization or prolongation of existing hospitalization; Congenital anomaly or birth defect; Other medically important events.
Time frame: baseline to day 3, week 1, 4, 12, 24, 36, 52
Changes in intraocular pressure (IOP) in Subjects
IOP refers to the fluid pressure inside the eye. Monitoring IOP ensures that interventions do not inadvertently increase IOP to dangerous levels. IOP will be measured using a clinical tonometry device.
Time frame: baseline to day 3, week 1, 4, 12, 24, 36, 52
Change of MLMT level
Multi-Luminance Mobility Test (MLMT) is used to evaluate how well individuals with visual impairments can navigate and perform tasks in different lighting conditions. This test is particularly relevant for conditions that affect night vision or light adaptation, such as retinitis pigmentosa or other forms of inherited retinal dystrophies.
Time frame: baseline to day 3, week 1, 4, 12, 24, 36, 52
Change of Quality of Life
Quality of Life will be measured using Visual Function Questionnaire (VFQ-25) or other similar questionnaires before and after treatment
Time frame: baseline to day 3, week 1, 4, 12, 24, 36, 52
Change in best corrected visual acuity (BCVA)
BCVA of both eyes will be assessed using the early treatment of diabetic retinopathy study (ETDRS) chart or tumbling "E" chart or other avaliable measurement. This approach was chosen to facilitate visual acuity testing in subject who cannot recognize letters.
Time frame: baseline to day 3, week 1, 4, 12, 24, 36, 52
Change in color discrimination
Color discrimination testing measures an individual's ability to perceive and differentiate hues across the visible spectrum under standard luminance level. Instead of relying on fine spatial detail, these tests challenge the visual system to detect subtle differences in wavelength-an ability that is often impaired in advanced retinal disease.
Time frame: baseline to day 3, week 1, 4, 12, 24, 36, 52
Change in visual field (VF)
Visual field will be assessed by Humphrey perimetry, changes in VFI, MD, PSD will be analyzed.
Time frame: baseline to day 3, week 1, 4, 12, 24, 36, 52
Change in Fundus Autofluorescence (FAF)
FAF is a non-invasive imaging technique that provides critical information about the health of the retina, which is vital for the functioning of the retina.
Time frame: baseline to day 3, week 1, 4, 12, 24, 36, 52
Change in central foveal thickness (CFT) using Optical Coherence Tomography (OCT)
Central Foveal Thickness refers to the thickness of the retina at the fovea, the central part of the macula. Changes in CFT can indicate various retinal conditions, including macular edema, macular degeneration, and central serous retinopathy.
Time frame: baseline to day 3, week 1, 4, 12, 24, 36, 52
Change in central macular thickness (CMT) using Optical Coherence Tomography (OCT)
Central Macular Thickness is the measurement of the thickness of the macula, which includes the fovea and the small surrounding area. The macula is responsible for central vision and visual acuity.
Time frame: baseline to day 3, week 1, 4, 12, 24, 36, 52
Changes in the fundus using fundus color photography
Fundus photography is used to document and monitor changes in the eye over time. It's vital for assessing the conditions of retina and monitoring the effects of treatments.
Time frame: baseline to day 3, week 1, 4, 12, 24, 36, 52
Change of MLCBT level
Multi-luminance chess board test (MLCBT) is a functional vision assessment specifically designed for individuals with severe visual impairment. During the test, participants are asked to identify the orientation of light target and avoid chessboard pattern obstacles presented under multiple illumination levels that simulate real-world environments, from very dim to bright light conditions. By evaluating performance across luminance tiers, MLCBT provides a sensitive measure of residual spatial vision and contrast-dependent functional gains, enabling the detection of clinically meaningful improvements that are not captured by conventional visual acuity testing.
Time frame: baseline to day 3, week 1, 4, 12, 24, 36, 52
Change of MLSDT level
The Multi-Luminance Shape Discrimination Test (MLSDT) evaluates functional vision by measuring a participant's ability to recognize geometric shapes presented at high contrast under different luminance levels. Shapes such as circles, squares, or triangles are shown one at a time, and the participant must correctly identify each target. By testing performance across a range of light intensities that mimic everyday environments, MLSDT sensitively captures changes in spatial perception and object recognition. This makes it particularly valuable for assessing treatment-related improvements in individuals with profound vision loss, where traditional acuity metrics may not reflect meaningful functional gains.
Time frame: baseline to day 3, week 1, 4, 12, 24, 36, 52
Change of FST outcome
The Full Stimulus Test (FST) is a test to assess the functional integrity of the entire visual pathway, from the retina to the visual cortex. It often used in studies involving retinal dystrophies or certain neuro-ophthalmological conditions, FST might be used to assess the efficacy of a treatment or intervention.
Time frame: baseline to day 3, week 1, 4, 12, 24, 36, 52
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Zhongmou Therapeutics